References
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–72. doi:10.1007/s10286-011-0119-5
- Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(11):1294–1309. doi:10.1016/j.jacc.2018.05.079
- Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567–1582. doi:10.1007/s00415-016-8375-x
- Claassen DO, Adler CH, Hewitt LA, Gibbons C. Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers. BMC Neurol. 2018;18(1):125. doi:10.1186/s12883-018-1129-x
- Merola A, Romagnolo A, Rosso M, et al. Autonomic dysfunction in Parkinson’s disease: a prospective cohort study. Mov Disord. 2018;33(3):391–397. doi:10.1002/mds.27268
- Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724–728. doi:10.1161/01.CIR.0000083721.49847.D7
- Northera® (droxidopa). Full Prescribing Information. Deerfield, IL: Lundbeck NA Ltd; 2017.
- Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, Phase 3 trial. Neurology. 2014;83(4):328–335. doi:10.1212/WNL.0000000000000615
- Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):101–107. doi:10.1161/HYPERTENSIONAHA.114.04035
- Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord. 2015;30(5):646–654. doi:10.1002/mds.26086
- Hauser RA, Hewitt LA, Isaacson S. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson’s disease (NOH306A). J Parkinsons Dis. 2014;4(1):57–65. doi:10.3233/JPD-130259
- Biaggioni I, Hewitt LA, Rowse GJ, Kaufmann H. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. BMC Neurol. 2017;17(1):90. doi:10.1186/s12883-017-0867-5
- Liu-Seifert H, Adams DH, Ascher-Svanum H, Faries DE, Kinon BJ. Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia. Patient Prefer Adherence. 2007;1:9–17.
- McDonell KE, Shibao CA, Biaggioni I, Hartman A, Robertson D, Claassen DO. Cognitive and behavioral changes in patients treated with droxidopa for neurogenic orthostatic hypotension: a retrospective review. Cogn Behav Neurol. 2019;32(3):179–184. doi:10.1097/WNN.0000000000000198
- Fanciulli A, Jordan J, Biaggioni I, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018;28(4):355–362. doi:10.1007/s10286-018-0529-8
- Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ. Safety and durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH303). J Parkinsons Dis. 2016;6(4):751–759. doi:10.3233/JPD-160860
- Isaacson S, Vernino S, Ziemann A, Rowse GJ, Kalu U, White WB. Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. J Am Soc Hypertens. 2016;10(10):755–762. doi:10.1016/j.jash.2016.07.010